Stallion India Fluorochemicals Limited

Stallion India Fluorochemicals Limited

192.92
INR
-4.00
(-2.03%)
5.39EPS
34.19P/E
21.39BMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
12.63
19.89
24.16
24.99
49.44
52.49
45.73
Basic EPS, GAAP
1.06
2.26
1.05
1.66
4.24
5.34
5.39
Free Cash Flow per Basic Share
-1.04
0.72
-0.3
-8.08
-2.37
-1.21
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
4.28
6.53
7.58
13.43
32.24
58.63
- -
Tangible Book Value per Share
4.28
6.53
7.58
13.43
32.24
58.63
- -
Basic Weighted Avg Shares
93
93
93
93
76
82
97
Sales/Revenue/Turnover
1,179
1,856
2,254
2,332
3,774
4,306
4,417
Operating Margin (%)
10.56
16.75
8.29
10.06
12.61
13.1
14.88
Depreciation Expense
14
18
15
11
12
15
16
Net Income, GAAP
98
211
98
155
323
438
520
Effective Tax Rate (%)
26.67
29.8
24.83
28.33
23.8
25.67
25.55
Profit Margin (%)
8.36
11.38
4.33
6.64
8.57
10.18
11.78
Working Capital
217
434
537
1,111
2,775
6,046
- -
LT Debt
- -
- -
- -
- -
- -
2
- -
Total Equity
399
609
707
1,253
3,008
6,806
- -
Return on Invested Capital (%)
- -
35.18
13.39
12.05
14.27
8.49
- -
Return on Capital (%)
- -
38.87
13.81
12.83
14.61
8.66
- -
Return on Common Equity (%)
- -
41.86
14.82
15.79
15.17
8.93
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
343
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
2
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
93
116
116
Market Capitalization
18,646
11,895
21,388

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
6,603
- -
Cash, Cash Equivalents & STI
- -
4,337
- -
Accounts Receivable, Net
- -
775
- -
Inventories
- -
1,266
- -
Total Current Liabilities
- -
557
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
343
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
82.45%
126.23%
Free Cash Flow
- -
428.55%
-44.94%
Net Income, GAAP
- -
52.75%
35.61%
Sales/Revenue/Turnover
- -
31.67%
14.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
732
676
852
1,516
3,774
2026
1,105
1,056
1,046
1,100
4,306
2027
1,214
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.9
0.09
1.05
1.55
4.24
2026
1.15
1.21
1.19
1.33
5.34
2027
1.6
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Shazad Sheriar Rustomji
Full Time Employees
30
Sector
Distribution services
Industry
Wholesale distributors
Address
2, A Wing, Knox Plaza Mumbai MA India 400064
IPO Date
Jan 23, 2025
Business
Stallion India Fluorochemicals Ltd engages in the debulking, blending, processing, and sale of refrigerant and industrial gases in India. The company manufactures and supplies fluorochemicals including hydrofluorocarbons (HFC) such as R-32, R-410A, R-404A, R-407C, hydrocarbons (HC), and hydrofluoroolefins (HFO) like R-1234yf; it also provides prefilled cans, small cylinders, and specialty gases for applications in air conditioners, refrigerators, firefighting equipment, semiconductor manufacturing, automobile production, pharmaceuticals, medicals, glass bottle manufacturing, aerosols, and spray foam. Stallion operates four plants in Khalapur and Panvel (Maharashtra), Manesar (Haryana), and Ghiloth (Rajasthan), with expansion underway at Khalapur for semiconductor and specialty gas facilities and a new refrigerant debulking plant in Mambattu, Andhra Pradesh. Founded in 1992 through predecessor operations and formally incorporated in 2002, the company is headquartered in Mumbai, India. Recent developments include its initial public offering listing on BSE and NSE in January 2025, an August 2025 memorandum of understanding with the Rajasthan government for a 10,000 MT R-32 manufacturing plant in Bhilwara with INR 200 crore investment and commercial production targeted for July 2026, and a November 2025 interest-free promoter infusion of INR 45.74 crore from share sales to accelerate the Bhilwara project without equity dilution.